Before the Bell Scans: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, August 14, 2013 LONDON, August 14, 2013 /PRNewswire/ -- On Tuesday, August 13, 2013, the U.S. equity market posted modest gains. The S&P 500 Index gained 0.28% to 1,694.16, the Dow Jones Industrial Average edged up 0.20% to 15,451.01, and the NASDAQ Composite Index closed 0.39% higher at 3,684.44. Shares in drug manufacturing companies ended higher, tracking gains in the broader market. The major movers in the sector included GlaxoSmithKline PLC (NYSE: GSK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), AstraZeneca PLC (NYSE: AZN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). All these companies are tracked by AAAResearchReports.com. Free technical research on GSK, KERX, AZN, and RPTP can be downloaded upon sign up at: http://www.aaaresearchreports.com/register/ GlaxoSmithKline PLC's stock edged higher on Tuesday, reversing some of its recent losses. The company's shares fluctuated between $51.42 and $52.03 before closing the day 1.38% higher at $52.01. A total of 2.48 million shares were traded which is above the daily average volume of 1.88 million. The stock has gained 0.68% in the last three trading sessions, compared to a loss of 0.20% in the S&P 500 during the same period. Moreover, the company's shares are currently trading near their 52-week high of $54.00, and also above their 50-day and 200-day moving averages. Sign up today to read free research report on GSK at: http://www.AAAResearchReports.com/GSK081413.pdf Keryx Biopharmaceuticals Inc.'s stock ended slightly higher on Tuesday, finishing at $8.97, up 0.34% from its previous closing price. The company's shares fluctuated between $8.79 and $8.98. A total of 0.89 million shares were traded which is below the daily average volume of 1.96 million. The company's shares have gained 10.60% in last one month, outperforming the S&P 500 which gained 0.83% during the same period. Register to download free technical analysis on KERX at: http://www.AAAResearchReports.com/KERX081413.pdf Shares in AstraZeneca PLC extended their gains from the previous trading session. The company's shares fluctuated between $51.00 and $51.48 before finishing the day 0.80% higher at $51.41. A total of 1.63 million shares were traded which is above the daily average volume of 1.55 million. The company's shares have gained 1.86% in the last three trading sessions and 3.69% in the last one month. The stock is currently trading near its 52-week high of $53.45. Moreover, company's shares are trading above their 50-day and 200-day moving averages. A free report on AZN can be accessed by registering at: http://www.AAAResearchReports.com/AZN081413.pdf Shares in Raptor Pharmaceuticals Corp. rose sharply on Tuesday, tracking gains in the broader market. The company's shares closed the day 1.51% higher at $10.77 after fluctuating between $10.40 and $10.80. A total of 0.41 million shares were traded which is above the daily average volume of 0.35 million. In the last three months, the stock has gained 82.85%, outperforming the S&P 500 which gained 3.70% during the same period. Additionally, the stock is trading above its 50-day and 200-day moving averages. Register with AAA Research Reports and download the research on RPTP for free at: http://www.AAAResearchReports.com/RPTP081413.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. AAAresearchreports.com SOURCE AAA Research Reports Contact: +1(646)396-9126
Before the Bell Scans: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp.